<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114283">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01863667</url>
  </required_header>
  <id_info>
    <org_study_id>3102-027</org_study_id>
    <secondary_id>2013-000301-23</secondary_id>
    <nct_id>NCT01863667</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027)</brief_title>
  <official_title>A Phase III, Multicenter, Double-Blind, Randomized Trial to Evaluate the Safety and Efficacy of MK-3102 Compared With Glimepiride in Subjects With Type 2 Diabetes Mellitus For Whom Metformin is Inappropriate Due to Intolerance or Contraindication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will assess the safety and efficacy of MK-3102 compared with the sulfonylurea,
      glimepiride, in Type 2 diabetes mellitus participants who are metformin intolerant or who
      have a contraindication to the use of metformin.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from Baseline in A1C at Week 54</measure>
    <time_frame>Baseline and Week 54</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experienced at Least One Adverse Event</measure>
    <time_frame>57 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Discontinued from the Study Due to an Adverse Event</measure>
    <time_frame>54 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fasting Plasma Glucose (FPG) at Week 54</measure>
    <time_frame>Baseline and Week 54</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving an A1C Goal &lt;7.0% and &lt;6.5% After 54 weeks of Treatment</measure>
    <time_frame>54 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Meeting the Composite Endpoint of an A1C Decrease &gt;0.5%, No Symptomatic Hypoglycemia, and No Body Weight Gain after 54 Weeks of Treatment</measure>
    <time_frame>54 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with an Adverse Event of Symptomatic Hypoglycemia</measure>
    <time_frame>54 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Body Weight at Week 54</measure>
    <time_frame>Baseline and Week 54</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>MK-3102</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive an MK-3102 25 mg capsule once weekly and glimepiride placebo tablet(s) once daily, for 54 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glimepiride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive glimepiride tablet(s) (1 mg or 2 mg, maximum dose 6 mg/day) once daily and an MK-3102 placebo capsule once weekly, for 54 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-3102</intervention_name>
    <arm_group_label>MK-3102</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride</intervention_name>
    <arm_group_label>Glimepiride</arm_group_label>
    <other_name>AMARYL®</other_name>
    <other_name>GLIMY</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-3102 Placebo</intervention_name>
    <arm_group_label>Glimepiride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride Placebo</intervention_name>
    <arm_group_label>MK-3102</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with Type 2 diabetes mellitus

          -  Have intolerability to metformin ≥1000 mg/day or have a contraindication to the use
             of metformin

          -  Females of reproductive potential agree to remain abstinent or use or have their
             partner use 2 acceptable methods of birth control

        Exclusion Criteria:

          -  History of type 1 diabetes mellitus or a history of ketoacidosis or assessed by the
             investigator as possibly having type 1 diabetes

          -  Has been treated with:

               1. A thiazolidinedione (TZD) within 4 months of study participation, or

               2. A glucagon-like peptide-1 (GLP-1) receptor mimetic or agonist (such as exenatide
                  or liraglutide) within 6 months of study participation, or

               3. Insulin within 12 weeks prior to study participation, or

               4. Dual antihyperglycemic agent (AHA) therapy within 12 weeks of study
                  participation (4 months if a component of the dual AHA therapy was a TZD)

               5. MK-3102 at any time prior to study participation

          -  On a weight loss program and is not in the maintenance phase; has started a weight
             loss medication in the past 6 months; or has undergone bariatric surgery within 12
             months prior to study participation

          -  Medical history of active liver disease (other than non-alcoholic hepatic steatosis),
             including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic
             gallbladder disease

          -  Human immunodeficiency virus

          -  New or worsening coronary heart disease, congestive heart failure, myocardial
             infarction, unstable angina, coronary artery intervention, stroke or transient
             ischemic neurological disorder within the past 3 months

          -  History of malignancy ≤5 years prior to study participation except for adequately
             treated basal cell or squamous cell skin cancer, or in situ cervical cancer

          -  Clinically important hematological disorder (such as aplastic anemia,
             myeloproliferative or myelodysplastic syndromes, thrombocytopenia)

          -  Pregnant or breast-feeding, or is expecting to conceive or donate eggs during the
             trial, including 21 days following the last dose of study drug
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
    <country>Austria</country>
    <country>Russian Federation</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Ukraine</country>
  </removed_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 29, 2014</lastchanged_date>
  <firstreceived_date>May 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
